Q-omics provides the consensus-scored ITGB8 profile across patient tissues and cancer cell-line models. ITGB8 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, ITGB8 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, ITGB8 RNA expression shows 18,970 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LGG, KICH, and UVM as cancer lineages where ITGB8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITGB8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITGB8 survival associations across molecular data types. ITGB8 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITGB8 RNA expression–survival associations across cancer types. High ITGB8 expression shows unfavorable associations in LGG, BLCA, UVM and OV, but favorable associations in SKCM and KIRC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for ITGB8 RNA expression.
This table summarizes ITGB8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ITGB8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITGB8 shows lower tumor expression in KICH and BRCA and higher tumor expression in HNSC, LUSC, COAD and LUAD. The KICH box plot shows higher ITGB8 RNA expression in normal versus tumor tissue (log2 FC = −2.917, t-test p < 0.001).
This table shows molecular features associated with ITGB8 in patient tissues and cancer cell lines. In patient samples, ITGB8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ITGB8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
